GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] appetite is doing more work than we give it credit for — 24 comments in the full submission. View in context.
178
c/glp1science·submitted 1 year ago by u/enzo_danquah

[Discussion] appetite is doing more work than we give it credit for

Discussionbranch of 6 comments

Something I keep coming back to: appetite is doing more work than we give it credit for. Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site. The GIP question, which is the most interesting unsettled thing in this field. Dual agonism at GIP and GLP-1…

Read the full submission and all 24 comments →

This branch

6 comments, started 1 year ago
u/gastric_emptying_gMOD27 points·1 year ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/vikram_mbeki7 points·1 year ago

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

replysharereportpermalink
u/aa_analysis_andy-6 points·1 year ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/not_my_main_nm1 point·1 year ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/dose_creep_dan1 point·1 year ago

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

replysharereportpermalink
u/farid_kuipers9 points·1 year ago

receptor distribution is why the side effects are where they are

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →